CompletedPHASE1, PHASE2NCT02332655
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
Studying Sturge-Weber syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Anne Comi, MD
- Principal Investigator
- Anne M Comi, MDHugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Intervention
- Cannabidiol(drug)
- Enrollment
- 5 enrolled
- Eligibility
- 45 years · All sexes
- Timeline
- 2014 – 2021
Study locations (1)
- Kennedy Krieger Institute, Baltimore, Maryland, United States
Collaborators
Jazz Pharmaceuticals · Faneca 66 Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02332655 on ClinicalTrials.govOther trials for Sturge-Weber syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT04717427Longitudinal Studies to Identify Biomarkers for Sturge-Weber SyndromeUniversity of Illinois at Chicago
- ACTIVE NOT RECRUITINGNANCT04517565Longitudinal Neuroimaging in Sturge-Weber SyndromeWayne State University
- ACTIVE NOT RECRUITINGNCT01425944Innovative Approaches to Gauge Progression of Sturge-Weber SyndromeHugo W. Moser Research Institute at Kennedy Krieger, Inc.